Jeito Capital renforce son soutien à Pulmocide en participant à un nouveau financement de 52 millions de dollars Jeito Capital renforce son soutien à Pulmocide en participant à un nouveau financement de 52 millions de dollars Ce nouveau tour de table permettra d’accélérer le développement clinique et...

Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision...

JEITO CAPITAL BECOMES A KEY PLAYER IN THE FINANCING OF LIFE SCIENCES IN EUROPE WITH THE CLOSING OF JEITO I AT €534 MILLION ($630 MILLION) JEITO CAPITAL BECOMES A KEY PLAYER IN THE FINANCING OF LIFE SCIENCES IN EUROPE WITH THE CLOSING OF JEITO I AT €534 MILLION ($630 MILLION)Jeito I exceeds target and becomes the largest European fund...

Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide Jeito selects Pulmocide as its fourth investment since launching the fundPulmocide is a late-stage biopharma...